文献速递类风湿关节炎

类风湿关节炎疾病活动度与肾功能下降:一项大型前瞻性登记研究

Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
PubMed 文献 · Ann Rheum Dis · 2025-01-02

该研究基于美国多中心前瞻性类风湿关节炎登记(2001—2022年),分析31 129例患者的时间平均临床疾病活动指数(TA-CDAI)与纵向估算肾小球滤过率(eGFR)变化的关系。结果显示,TA-CDAI活动度越高,eGFR年下降越快,CKD G3a和G3b期发生风险越高。

要点

  • TA-CDAI缓解组年均eGFR下降-0.83 mL/min/1.73 m2,低、中、高活动度组分别额外年下降-0.09、-0.17、-0.18 mL/min/1.73 m2。
  • 与TA-CDAI缓解相比,中、高活动度组CKD G3a风险升高(HR 1.22、1.27),低活动度组HR 1.15。
  • CKD G3b风险在高活动度组HR 1.93、中活动度组HR 1.66,低活动度组HR 1.22(95%CI 0.84至1.76)。

核心结论

  • 较高的类风湿关节炎疾病活动度与eGFR加速下降及临床相关肾功能不全风险增加相关。
  • 未来干预性研究应尝试重复验证类风湿关节炎疾病活动度与eGFR之间的关联。

研究设计与样本

  • 研究分析了美国2001年至2022年的多中心前瞻性类风湿关节炎登记数据。
  • 暴露为自研究入组起更新的时间平均临床疾病活动指数(TA-CDAI)分类。
  • 主要结局为纵向估算肾小球滤过率(eGFR)变化,次要结局为CKD G3a期(eGFR<60 mL/min/1.73 m2)和G3b期(eGFR<45 mL/min/1.73 m2)的发生。
  • 共纳入31 129例患者(中位年龄58.0岁,女性76.3%,中位eGFR 90.7 mL/min/1.73 m2),贡献234 973次访视和146 778人年随访。
  • 结果校正了相关的时间固定协变量和时间变化协变量。

主要发现

  • 多变量混合效应线性模型显示,TA-CDAI缓解组随访期间年均eGFR下降为-0.83 mL/min/1.73 m2。
  • 与缓解组相比,低活动度组额外年下降-0.09(95%CI -0.15至-0.03)mL/min/1.73 m2,中活动度组-0.17(95%CI -0.23至-0.10)mL/min/1.73 m2,高活动度组-0.18(95%CI -0.27至-0.08)mL/min/1.73 m2。
  • 与TA-CDAI缓解相比,随访期间CKD G3a的校正HR(95%CI)为低活动度组1.15(1.01至1.30)、中活动度组1.22(1.06至1.40)、高活动度组1.27(1.05至1.52)。
  • 与TA-CDAI缓解相比,随访期间CKD G3b的校正HR(95%CI)为低活动度组1.22(0.84至1.76)、中活动度组1.66(1.12至2.45)、高活动度组1.93(1.16至3.20)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA). The association of longitudinal RA disease activity with long-term kidney function has remained uncertain. METHOD: We analysed a multicentre prospective RA registry in the USA from 2001 to 2022. The exposure was updated time-averaged Clinical Disease Activity Index (TA-CDAI) categories from study enrolment. The primary outcome was a longitudinal estimated glomerular filtration rate (eGFR) change. Secondary outcomes included developments of CKD stage G3a (eGFR<60 mL/min/1.73 m2) and stage G3b (eGFR<45 mL/min/1.73 m2). Results were adjusted for relevant time-fixed and time-varying covariates. RESULTS: 31 129 patients (median age: 58.0 years, female: 76.3%, median eGFR: 90.7 mL/min/1.73 m2) contributed 234 973 visits and 146 778 person-years of follow-up. Multivariable mixed-effect linear model showed an average annual eGFR decline during follow-up in the TA-CDAI-remission group of -0.83 mL/min/1.73 m2 and estimated additional annual declines (95% CI) of -0.09 (-0.15 to -0.03) in low, -0.17 (-0.23 to -0.10) in moderate and -0.18 (-0.27 to -0.08) mL/min/1.73 m2 in high disease activity patients. Compared with TA-CDAI remission, adjusted HRs (95% CI) for CKD stage G3a during follow-up were 1.15 (1.01 to 1.30) in low, 1.22 (1.06 to 1.40) in moderate and 1.27 (1.05 to 1.52) in high disease activity; for CKD stage G3b, 1.22 (0.84 to 1.76) in low, 1.66 (1.12 to 2.45) in moderate and 1.93 (1.16 to 3.20) in high disease activity. CONCLUSIONS: Higher RA disease activity was associated with accelerated eGFR decline and increased risk of clinically relevant kidney dysfunction. Future intervention studies should attempt to replicate the association between RA disease activity and eGFR.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fukui S, Winkelmayer WC, Tedeschi SK, et al. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025. PMID: 39919894. doi:10.1136/ard-2024-226156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。